Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Rheumatology

Beyond the Joints: Monitoring the Eyes and Gut in ERA-JIA

At a Glance

Enthesitis-Related Arthritis (ERA-JIA) is a systemic condition that can cause severe inflammation outside the joints, particularly acute eye inflammation (uveitis) and Inflammatory Bowel Disease (IBD). Regular eye exams and monitoring for gut issues are essential for your child's long-term health.

While Enthesitis-Related Arthritis (ERA) primarily affects the joints and tendons, it is a systemic (body-wide) condition. This means the same inflammation that causes heel or back pain can also target the eyes and the digestive system [1]. Understanding these “extra-articular” (outside the joints) complications is essential for protecting your child’s long-term health.

The Eyes: Acute vs. Silent Uveitis

In many forms of childhood arthritis, eye inflammation—called uveitis—is “silent,” meaning the child has no symptoms while damage is occurring [2]. However, in ERA-JIA, uveitis often behaves differently [3].

  • The “Red Eye” Warning: In children with ERA (especially those who are HLA-B27 positive), uveitis is frequently “acute” [4]. This means it often comes on suddenly with clear warning signs: redness, sharp pain, and intense sensitivity to light (photophobia) [5].
  • One Eye at a Time: Unlike the “silent” type, this form often affects only one eye at a time, though it can flip-flop between eyes or recur in the same eye [5][6].
  • Screening: Because eye inflammation can still occur without obvious symptoms, the standard of care includes regular screenings with an ophthalmologist using a slit-lamp (a specialized microscope for the eye) [7][8]. These screenings should begin as soon as the arthritis is diagnosed [9].

The Gut: The ERA-IBD Connection

There is a strong biological link between the inflammation in ERA and Inflammatory Bowel Disease (IBD), such as Crohn’s disease or ulcerative colitis [10].

Research shows that children with ERA are at a higher risk of developing IBD than children with other types of arthritis [10]. This is partly because they share similar “inflammatory pathways,” including the IL-23/IL-17 axis mentioned in previous chapters [11][12].

The “Etanercept Paradox”

When it comes to treating ERA, your doctor’s choice of medication is often influenced by the health of your child’s gut.

A well-known phenomenon in rheumatology is the “paradoxical effect” of a medication called etanercept [13]. While etanercept is excellent for treating joint swelling, it has a unique profile:

  • Ineffective for Gut: Unlike other TNF inhibitors, etanercept does not work to treat IBD [14][15].
  • The Paradox: In some children with ERA, etanercept has been associated with the new onset of IBD symptoms, such as abdominal pain, weight loss, or chronic diarrhea [10][16].

Because of this, if a child with ERA shows any signs of gut issues, or if they have a strong family history of Crohn’s, doctors often prefer “monoclonal antibody” TNF inhibitors like adalimumab or infliximab [17]. These medications are powerful “two-for-one” treatments that can manage both the arthritis and the gut inflammation at the same time [18][19].

Watching for “Red Flags”

As a parent, you are the first line of defense. If your child is on treatment for ERA and develops any of the following, contact your rheumatologist immediately:

  • Sudden, painful red eyes [5].
  • Persistent stomach pain or cramping [19].
  • Blood in the stool or unexplained weight loss [10].

Early detection of these symptoms allows for a quick adjustment in medication, often preventing more serious complications in the eyes or digestive tract [20].

Common questions in this guide

How does eye inflammation in ERA differ from other types of juvenile arthritis?
In ERA, eye inflammation (uveitis) often comes on suddenly with obvious warning signs like redness, sharp pain, and severe sensitivity to light. In many other forms of childhood arthritis, uveitis is silent and causes no immediate symptoms.
Why do children with ERA need regular eye exams if they don't have symptoms?
While ERA often causes obvious eye symptoms, silent inflammation can still occur. Regular screening with an ophthalmologist using a specialized slit-lamp microscope is necessary to catch and treat any hidden inflammation before it causes permanent damage.
Is there a connection between ERA and inflammatory bowel disease (IBD)?
Yes, children with ERA have a higher risk of developing inflammatory bowel disease, such as Crohn's disease or ulcerative colitis. This happens because both conditions share similar biological inflammatory pathways in the body.
Why might my doctor choose adalimumab instead of etanercept for my child's ERA?
While etanercept is excellent for treating joint swelling, it does not treat gut inflammation and can sometimes trigger new IBD symptoms. If your child has gut issues or a family history of Crohn's, doctors often prefer medications like adalimumab that treat both the joints and the gut.
What warning signs should I watch for in my child with ERA?
Contact your rheumatologist immediately if your child develops sudden and painful red eyes, persistent stomach cramping, unexplained weight loss, or blood in their stool. Early detection allows doctors to quickly adjust medications and prevent serious complications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How does the uveitis risk for my child with ERA differ from other types of JIA, and what specific symptoms should we watch for?
  2. 2.Given the link between ERA and IBD, are there specific markers in my child's bloodwork (like calprotectin or iron levels) we should monitor?
  3. 3.If we decide to use a TNF inhibitor, why might you choose adalimumab or infliximab over etanercept for my child?
  4. 4.How often should my child have a slit-lamp exam with an ophthalmologist, even if they have no eye symptoms?
  5. 5.What is the plan if my child develops stomach pain or changes in bowel habits while on their current arthritis medication?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Enthesitis-Related Juvenile Idiopathic Arthritis.

    Rosenthal A, Janow G

    Pediatrics in review 2019; (40(5)):256-258 doi:10.1542/pir.2017-0177.

    PMID: 31043447
  2. 2

    Juvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches.

    Quartier P

    Journal of clinical medicine 2021; (10(13)) doi:10.3390/jcm10132934.

    PMID: 34208973
  3. 3

    Ocular features of the HLA-B27-positive seronegative spondyloarthropathies.

    Jhaj G, Kopplin LJ

    Current opinion in ophthalmology 2018; (29(6)):552-557 doi:10.1097/ICU.0000000000000525.

    PMID: 30148724
  4. 4

    Uveitis in Spondyloarthritis: An Overview.

    Cantini F, Nannini C, Cassarà E, et al.

    The Journal of rheumatology. Supplement 2015; (93()):27-9 doi:10.3899/jrheum.150630.

    PMID: 26523051
  5. 5

    Extra-Articular Manifestations in Patients with Ankylosing Spondylitis: Baseline Characteristics from the RBSMR Study.

    Ouardi NE, Djossou JH, Taoubane L, et al.

    Mediterranean journal of rheumatology 2022; (33(3)):316-321 doi:10.31138/mjr.33.3.316.

    PMID: 36531422
  6. 6

    Acute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye.

    Khan MA, Haroon M, Rosenbaum JT

    Current rheumatology reports 2015; (17(9)):59 doi:10.1007/s11926-015-0536-x.

    PMID: 26233598
  7. 7

    Assessing Barriers to Uveitis Screening in Patients with Juvenile Idiopathic Arthritis Through Semi-Structured Interviews.

    Ballenger LR, Ardoin SP, Driest KD

    Pediatric quality & safety 2018; (3(3)):e084 doi:10.1097/pq9.0000000000000084.

    PMID: 30229196
  8. 8

    An update on the modern management of paediatric uveitis.

    Choi J, Hawley DP, Ashworth J, et al.

    The British journal of ophthalmology 2019; (103(12)):1685-1689 doi:10.1136/bjophthalmol-2019-314212.

    PMID: 31272956
  9. 9

    Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study.

    Rypdal V, Glerup M, Songstad NT, et al.

    Ophthalmology 2021; (128(4)):598-608 doi:10.1016/j.ophtha.2020.08.024.

    PMID: 32866542
  10. 10

    Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use.

    van Straalen JW, Krol RM, Giancane G, et al.

    Rheumatology (Oxford, England) 2022; (61(5)):2104-2112 doi:10.1093/rheumatology/keab678.

    PMID: 34508559
  11. 11

    Exploring the Mechanism of Berberine Intervention in Ulcerative Colitis from the Perspective of Inflammation and Immunity Based on Systemic Pharmacology.

    Jiang Y, Zhao L, Chen Q, Zhou L

    Evidence-based complementary and alternative medicine : eCAM 2021; (2021()):9970240 doi:10.1155/2021/9970240.

    PMID: 34211579
  12. 12

    Review article: the genetics of the human leucocyte antigen region in inflammatory bowel disease.

    Ashton JJ, Latham K, Beattie RM, Ennis S

    Alimentary pharmacology & therapeutics 2019; (50(8)):885-900 doi:10.1111/apt.15485.

    PMID: 31518029
  13. 13

    Editorial: anti-TNF therapy-a double-edged sword?

    Schreiner P, Biedermann L

    Alimentary pharmacology & therapeutics 2019; (50(7)):822-823 doi:10.1111/apt.15401.

    PMID: 31532545
  14. 14

    Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy.

    Iriarte A, Zaera C, Bachiller-Corral J, López-Sanromán A

    Gastroenterologia y hepatologia 2017; (40(2)):117-121 doi:10.1016/j.gastrohep.2016.01.011.

    PMID: 26993096
  15. 15

    Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?

    Nehring P, Przybyłkowski A

    Pharmaceutical medicine 2020; (34(4)):257-262 doi:10.1007/s40290-020-00340-1.

    PMID: 32514931
  16. 16

    New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors.

    Zeitz J, Enderlin S, Biedermann L, et al.

    Case reports in gastroenterology 2015; (9(1)):106-12 doi:10.1159/000381637.

    PMID: 26034472
  17. 17

    Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.

    Derakhshan MH, Dean L, Jones GT, et al.

    RMD open 2020; (6(2)) doi:10.1136/rmdopen-2020-001206.

    PMID: 32641447
  18. 18

    Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature.

    Tolu S, Rezvani A, Hindioglu N, Calkin Korkmaz M

    Rheumatology international 2018; (38(11)):2157-2162 doi:10.1007/s00296-018-4165-3.

    PMID: 30293157
  19. 19

    Antitumor Necrosis Factor-α Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review.

    Bieber A, Fawaz A, Novofastovski I, Mader R

    The Journal of rheumatology 2017; (44(7)):1088-1095 doi:10.3899/jrheum.160952.

    PMID: 28412712
  20. 20

    Rheum for Improvement? Delayed Diagnosis of Juvenile Idiopathic Arthritis: A Narrative Review.

    Costello A, Rasooly I, Weiss P

    Arthritis care & research 2025; (77(3)):283-290 doi:10.1002/acr.25438.

    PMID: 39308000

This page provides educational information on eye and gut complications related to ERA-JIA. It does not replace professional medical advice. Always contact your pediatric rheumatologist or ophthalmologist immediately if your child develops new eye or digestive symptoms.

Get notified when new evidence is published on Enthesitis-related juvenile idiopathic arthritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.